-
Product Name
COMMD5 antibody
- Documents
-
Description
COMMD5 Rabbit Polyclonal antibody. Positive IP detected in mouse heart tissue. Positive WB detected in mouse kidney tissue, HEK-293 cells, human heart tissue, human stomach tissue, mouse heart tissue, mouse stomach tissue. Observed molecular weight by Western-blot: 25-28 kDa
-
Tested applications
ELISA, WB, IP
-
Species reactivity
Human,Mouse,Rat; other species not tested.
-
Alternative names
COMM domain containing 5 antibody; COMMD5 antibody; FLJ13008 antibody; HCARG antibody; HT002 antibody
-
Isotype
Rabbit IgG
-
Preparation
This antibody was obtained by immunization of COMMD5 recombinant protein (Accession Number: NM_001081004). Purification method: Antigen affinity purified.
-
Clonality
Polyclonal
-
Formulation
PBS with 0.1% sodium azide and 50% glycerol pH 7.3.
-
Storage instructions
Store at -20℃. DO NOT ALIQUOT
-
Applications
Recommended Dilution:
WB: 1:500-1:5000
IP: 1:200-1:2000
-
Validations
mouse kidney tissue were subjected to SDS PAGE followed by western blot with Catalog No:109444(COMMD5 antibody) at dilution of 1:1000
IP Result of anti-COMMD5 (IP:Catalog No:109444, 4ug; Detection:Catalog No:109444 1:500) with mouse heart tissue lysate 3200ug.
-
Background
COMM domain containing 5 (COMMD5, synonyms: HCARG, HT002) is a hypertension-related calcium-regulated gene. COMMD5 is negatively regulated by extracellular calcium concentration, and its basal mRNA levels were higher in hypertensive animals. Tissue distribution of COMMD5 shows a preponderance in the heart, stomach, jejunum, kidney (tubular fraction), liver, and adrenal gland (mainly in the medulla). COMMD5 mRNA is significantly more expressed in adult than in fetal organs, and its levels are decreased in tumors and cancerous cell lines. COMMD5 protein has no transmembrane domain, but contains 67% -helix content, a calcium-binding site, four putative "leucine zipper" motifs, and a nuclear receptor-binding domain. At the subcellular level, COMMD5 shows a nuclear localization.
-
References
- Chen BL, Yu J, Zeng ZR. Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression. Oncology reports. 20(5):1093-7. 2008.
- Matsuda H, Lavoie JL, Gaboury L, Hamet P, Tremblay J. HCaRG accelerates tubular repair after ischemic kidney injury. Journal of the American Society of Nephrology : JASN. 22(11):2077-89. 2011.
Related Products / Services
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"